Patients receiving 25 mg, 100 mg, or 200 mg of fazirsiran who had baseline fibrosis (n=16) demonstrated a dose dependent mean reduction in serum mutant alpha-1 antitrypsin protein (Z-AAT) ...
- AATD-LD is a Rare Genetic Disease Affecting Children and Adults with no Approved Treatments - Takeda and Arrowhead are Advancing Fazirsiran and Actively Enrolling in 160 patient Phase 3 REDWOOD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback